首页> 美国卫生研究院文献>British Journal of Clinical Pharmacology >The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.
【2h】

The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.

机译:CYP2D6在右美沙芬的初级和次级氧化代谢中的作用:使用人肝微粒体的体外研究。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. The enzyme kinetics of dextromethorphan O-demethylation in liver microsomes from three extensive metabolisers (EM) with respect to CYP2D6 indicated high (Km1 2.2-9.4 microM) and low (Km2 55.5-307.3 microM) affinity sites whereas microsomes from two poor metabolisers (PM) indicated a single site (Km 560 and 157 microM). Similar differences were shown for 3-methoxymorphinan O-demethylation to 3-hydroxymorphinan (Km 6.9-9.6 microM in EM subjects; Km 307 and 213 microM in PM subjects). 2. Dextromethorphan O-demethylation was inhibited competitively by quinidine (Ki 0.1 microM), rac-perhexiline (Ki 0.4 microM), dextropropoxyphene (Ki 6 microM), rac-methadone (Ki 8 microM), and 3-methoxymorphinan (Ki 15 microM). These compounds were also potent inhibitors of 3-methoxymorphinan O-demethylation with IC50 values ranging from 0.02-12 microM. Anti-LKM1 serum inhibited both dextromethorphan and 3-methoxymorphinan O-demethylations in a titre-dependent manner. 3. The Michaelis-Menten constant for dextromethorphan N-demethylation to 3-methoxymorphinan (Km 632-977 microM) and dextrorphan N-demethylation to 3-hydroxymorphinan (Km 1571-4286 microM) did not differ between EM and PM microsomes. These N-demethylation reactions were not inhibited by quinidine and rac-methadone or LKM1 antibodies. 4. Dextromethorphan and 3-methoxymorphinan are metabolised by the same P450 isoform, CYP2D6, whereas the N-demethylation reactions are not carried out by CYP2D6.
机译:1.相对于CYP2D6,来自三个广泛代谢者(EM)的肝微粒体中右美沙芬O-去甲基化的酶动力学表明高(Km1 2.2-9.4 microM)和低(Km2 55.5-307.3 microM)亲和力位点,而来自两个不良代谢者的微粒体(PM)表示单个位点(Km 560和157 microM)。对于3-甲氧基吗啡喃O-去甲基化为3-羟基吗啡喃显示出相似的差异(EM受试者中为Km 6.9-9.6 microM; PM受试者中为Km 307和213 microM)。 2.奎尼丁(Ki 0.1 microM),rac-perhexiline(Ki 0.4 microM),右丙氧吩(Ki 6 microM),rac-美沙酮(Ki 8 microM)和3-甲氧吗啡喃(Ki 15 microM)竞争性抑制右美沙芬O-去甲基化)。这些化合物也是3-甲氧基吗啡喃O-去甲基化的有效抑制剂,IC50值为0.02-12 microM。抗LKM1血清以滴度依赖性方式抑制右美沙芬和3-甲氧基吗啡喃的O-去甲基化。 3. EM和PM微粒体的右美沙芬N-去甲基化为3-甲氧基吗啡喃(Km 632-977 microM)和右美沙芬N-去甲基化为3-羟基吗啡喃(Km 1571-4286 microM)的Michaelis-Menten常数在EM和PM微粒体之间没有差异。这些N-去甲基化反应不受奎尼丁和rac-美沙酮或LKM1抗体的抑制。 4.右美沙芬和3-甲氧基吗啡喃被同一P450亚型CYP2D6代谢,而N-去甲基化反应不是由CYP2D6进行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号